top of page
ON THE PULSE  

Highlights on biomedical research 

Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.

BY:

Michelle

LeeFeb 11, 2026

  • 微信图片_20260414172211_190_280
  • 微信图片_20260414172239_191_280

Burn-associated cholestasis (BAC) is a common complication following severe burn injuries, characterised by elevated liver enzymes and bilirubin levels. A study examined the clinical significance and prognostic value of cholestasis patterns in burn patients admitted to intensive care units. The researchers identified three distinct categories: BAC-A (elevated alkaline phosphatase and gamma-glutamyltransferase without hyperbilirubinemia), BAC-B (elevated enzymes with elevated bilirubin), and BAC-C (hyperbilirubinemia alone). Risk factors independently associated with BAC development included higher burn severity scores, ketamine use, mechanical ventilation, and parenteral nutrition. Importantly, bilirubin trajectories emerged as early predictors of mortality risk, with dynamic changes in cholestasis parameters providing critical prognostic information. These findings highlight that cholestasis in burn patients is highly dynamic rather than static, and monitoring bilirubin dynamics could guide clinical decision-making and identify high-risk patients requiring intensive intervention.2

 

Reference:

2. Semmler L, Semmler G, Langa A, et al. Characterisation and Prognostic Implication of Cholestasis After Burn Injury. Aliment Pharmacol Ther. 2026;0:1-11.

POPULAR STORY

Uncovering the Tricks of the Silent Thief of Sight

Dr. Roy Lau

Dec 19, 2024

What’s New in Coronary Artery Disease?

Dr. Roy Lau

Aug 20, 2024

Challenges and Strategies for Managing CHB Patients with Co-morbidities

Dr. Roy Lau

Jun 21, 2024

Decoding the Paradox on Impact of Obesity on Cognitive Functioning

Dr. Roy Lau

Jun 20, 2024

Gain Without Pain – Revisiting the Pain Management in Rheumatoid Arthritis

Dr. Roy Lau

Oct 22, 2024

Uncovering the Art of Perfect Matching – A Review on Precision Oncology

Dr. Roy Lau

Feb 17, 2025

bottom of page